By Laiba Immad
Publication Date: 2026-01-18 05:54:00
We recently compiled a list of the 10 Best Investments During A Recession. Thermo Fisher Scientific Inc. is placed second on our list.
TheFly reported on January 9 that Stifel analyst Daniel Arias maintained a Buy rating on TMO and significantly raised the price target to $700 from $583, an increase of $117. According to Arias, the company is anticipating a “solid year” in which organic growth returns to mid-single digits and is modifying its methodology to account for 2027 profits potential. The biopharma industry’s anticipated comeback and strong single-digit EPS growth are the main sources of this optimism.
Separately, on January 12, Thermo Fisher Scientific Inc. (NYSE:TMO) and NVIDIA Corporation announced a strategic partnership to integrate advanced AI into laboratory workflows. In addition to creating “lab-in-the-loop” solutions that link instruments and data to AI software at scale, the partnership will make use of NVIDIA’s DGX Spark supercomputer and BioNeMo models to modernize tasks like experiment planning and data processing.
The collaboration intends to speed up pharmaceutical discovery, improve research accuracy, and boost operational efficiency by fusing NVIDIA’s AI infrastructure with TMO’s life science expertise. This is a “trinity of AI, agents, and instruments” that is changing scientific…